21例肺诺卡菌病临床特征及耐药性分析

doi:10.19871/j.cnki.xfcrbzz.2024.04.007

新发传染病电子杂志 ›› 2024, Vol. 9 ›› Issue (4): 34-38.doi: 10.19871/j.cnki.xfcrbzz.2024.04.007

21例肺诺卡菌病临床特征及耐药性分析

梅琳¹, 陈华², 张妍蓓³, 刘盛盛¹

1.安徽省胸科医院结核七科;安徽合肥 230022;
2.广州市胸科医院非结核分枝杆菌病诊疗中心/呼吸疾病国家重点实验室,广东广州 510095;
3.安徽医科大学第一附属医院呼吸与危重症科,安徽合肥 230022

收稿日期:2024-03-21 出版日期:2024-08-31 发布日期:2024-10-10
通讯作者: 刘盛盛,Email：liushengsheng1014@163.com
基金资助:
1.安徽省自然科学基金项目（2208085MH193）; 2.广东省医学科学技术研究基金项目（C2021090）

Analysis of strain distribution, clinical characteristics and antimicrobial susceptibility in 21 cases pulmonary nocardiosis

Mei Lin¹, Chen Hua², Zhang Yanbei³, Liu Shengsheng¹

1. Tuberculosis Department 7, Anhui Chest Hospital, Anhui Hefei 230022, China;
2. Non-Tuberculous Mycobacterial Diseases Diagnosis and Treatment Center, Guangzhou Chest Hospital, State Key laboratory of Respiratory Disease, Guangdong Guangzhou 510095, China;
3. Respiratory and Critical Care Medicine Department, The First Affiliated Hospital of Anhui Medical University, Anhui Hefei 230022, China

Received:2024-03-21 Online:2024-08-31 Published:2024-10-10

摘要/Abstract

摘要： 目的了解肺诺卡菌的菌种分布、感染特征及菌种耐药情况,为肺诺卡菌病的诊断和治疗提供依据。方法回顾性分析2021年1月至2023年12月在安徽省胸科医院确诊为肺诺卡菌病患者的临床资料,分析诺卡菌菌种分布、临床特点及耐药情况。结果 21例肺诺卡菌病确诊患者共鉴定出诺卡菌22株,其中1例有合并感染。菌种包括盖尔森基兴诺卡菌7株（31.8%）、皮疽诺卡菌4株（18.2%）、脓肿诺卡菌2株（9.1%）、豚鼠耳炎诺卡菌2株（9.1%）、星型诺卡菌、华莱士诺卡菌、亚洲诺卡菌和南非诺卡菌各1株（4.5%）,另有3株（13.6%）未能鉴别种属。患者平均年龄60.8岁,男女性别比为1∶1.1,症状主要表现为咳嗽/咳痰（85.7%）、胸闷（38.1%）、咯血（28.6%）等;胸部CT主要表现为支气管扩张（57.1%）及斑片状影（57.1%）等;气管镜可直观清晰展示气管内黏液、糜烂或血凝块等典型病变特征。11例药物敏感试验结果显示诺卡菌对利奈唑胺、阿米卡星敏感。结论肺诺卡菌病多为中老年患者,男女比例相当,感染菌种主要为盖尔森基兴诺卡菌,对利奈唑胺、阿米卡星敏感。患者临床表现不具备特异性,CT及电子支气管镜下表现具有一定的辅助诊断价值。

关键词: 诺卡菌, 菌种鉴定, 临床特征, 耐药性

Abstract: Objective To understand the distribution of strains of Nocardia pseudomallei, infection characteristics and strain resistance of Nocardia pseudomallei, and to provide a basis for the diagnosis and treatment of pulmonary nocardiosis. Method Clinical data of patients diagnosed with pulmonary nocardiosis in Anhui Chest Hospital from January 2021 to December 2023 were retrospectively analysed to analyse the distribution of Nocardia strains, clinical characteristics and drug resistance. Result A total of 22 strains of Nocardia were identified in 21 patients with confirmed pulmonary nocardiosis, including one case with co-infection. The strains included 7 strains (31.8%) of Nocardia gelsenkirchen, 4 strains (18.2%) of Nocardia dermatoglycans, 2 strains (9.1%) of Nocardia abscessus, 2 strains (9.1%) of Nocardia guinea-pig otitis, and 1 strain (4.5%) of each of Nocardia asteroidea, Nocardia Wallace, Nocardia asiatica and Nocardia africanica, and 3 strains (13.6%) could not be identified to the species genus. The average age of the patients was 60.8 years old, and the sex ratio was 1:1.1. Symptoms mainly included cough/sputum (85.7%), chest tightness (38.1%), hemoptysis (28.6%), etc. Chest CT mainly showed bronchial dilatation (57.1%) and plaque (57.1%), etc. Bronchoscopy could visualize and clearly show the typical characteristics of the lesions such as mucus, vesiculocytes, or blood clots in the trachea. The results of drug sensitivity test in 11 cases showed that Nocardia was sensitive to linezolid and amikacin. Conclusion Pulmonary nocardiosis is mostly in middle-aged and elderly patients, with equal proportion of men and women, and the infecting strain is mainly Nocardia gelsenkirchen, which is sensitive to linezolid and amikacin. The clinical manifestations of the patients were not specific, and CT and electronic bronchoscopic manifestations had certain auxiliary diagnostic value.

Key words: Nocardia, Strain identification, Clinical features, Drug resistance

中图分类号:

R519

梅琳, 陈华, 张妍蓓, 刘盛盛. 21例肺诺卡菌病临床特征及耐药性分析[J]. 新发传染病电子杂志, 2024, 9(4): 34-38.

Mei Lin, Chen Hua, Zhang Yanbei, Liu Shengsheng. Analysis of strain distribution, clinical characteristics and antimicrobial susceptibility in 21 cases pulmonary nocardiosis[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(4): 34-38.

参考文献

[1] TRAXLER RM, BELL ME, LASKER B, et al.Updated Review on Nocardia Species: 2006-2021[J]. Clin Microbiol Rev, 2022, 35(4):e0002721.
[2] GUPTA S, GRANT LM, POWERS HR, et al.Invasive Nocardia Infections across Distinct Geographic Regions, United States[J]. Emerg Infect Dis, 2023, 29(12): 2417-2425.
[3] WANG H, ZHU Y, CUI Q, et al.Epidemiology and Antimicrobial Resistance Profiles of the Nocardia Species in China, 2009 to 2021[J]. Microbiol Spectr, 2022, 10(2): e0156021.
[4] METLAY J, WATERER G, LONG A, et al.Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America[J]. Am J Respir Crit Care Med, 2019, 200(7):45-67.
[5] 赵雁林, 逄宇. 结核病实验室检验规程[M]. 北京:人民卫生出版社, 2015.
[6] CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI).Susceptibility testing of Mycobacteria, Nocardia spp., and other aerobic actinomycetes. 3rd ed[M].PA: Clinical and Laboratory Standards Institute, 2018.
[7] YEOH K, GLOBAN M, NAIMO P, et al.Identification and antimicrobial susceptibility of referred Nocardia isolates in Victoria, Australia 2009-2019[J]. J Med Microbiol, 2022, 71(8).
[8] WENG SS, ZHANG HY, AI JW, et al.Rapid Detection of Nocardia by Next-Generation Sequencing[J]. Front Cell Infect icrobiol, 2020,10: 13.
[9] UHDE KB, PATHAK S, MCCULLUM I JR, et al.Antimicrobial-resistant nocardia isolates, United States, 1995-2004[J]. Clin Infect Dis, 2010, 51(12): 1445-1448.
[10] YARBROUGH ML, LAINHART W, BURNHAM CD.Identification of Nocardia, Streptomyces, and Tsukamurella using MALDI-TOF MS with the Bruker Biotyper[J]. Diagn Microbiol Infect Dis, 2017, 89(2): 92-97.
[11] TREMBLAY J, THIBERT L, ALARIE I, et al.Nocardiosis in Quebec, Canada, 1988-2008[J]. Clin Microbiol Infect, 2011, 17(5): 690-696.
[12] PINTADO V, GÓMEZ-MAMPASO E, FORTÚN J, et al.Infection with Nocardia species: clinical spectrum of disease and species distribution in Madrid, Spain, 1978-2001[J]. Infection, 2002, 30(6): 338-340.
[13] LEBEAUX D, BERGERON E, BERTHET J, et al.Antibiotic susceptibility testing and species identification of Nocardia isolates:a retrospective analysis of data from a French expert laboratory, 2010-2015[J]. Clin Microbiol Infect, 2019, 25(4): 489-495.
[14] BLOSSER SJ, DRAKE SK, ANDRASKO JL, et al.Multicenter Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Study for Identification of Clinically Relevant Nocardia spp[J]. J Clin Microbiol, 2016, 54(5): 1251-1258.
[15] VERROKEN A, JANSSENS M, BERHIN C, et al.Evaluation of matrix-assisted laserdesorption ionization-time of flight mass spectrometry for identification of nocardia species[J]. J Clin Microbiol, 2010, 48(11): 4015-4021.
[16] WEI M, WANG P, QU J, et al.Identification and antimicrobial susceptibility of clinical Nocardia species in a tertiary hospital in China[J]. J Glob Antimicrob Resist, 2017, 11: 183-187.
[17] 陈莹, 贾艳增, 时东彦, 等. 河北地区多中心临床分离诺卡菌菌种分布[J]. 临床检验杂志, 2020, 38(10): 790-792.
[18] 程振娜, 李刚, 殷国民, 等. 诺卡菌感染的临床特点及耐药性分析[J]. 中华医院感染学杂志, 2018, 28(6): 818-821.
[19] 杜艳, 马爱平, 王广东, 等. 应用宏基因组二代测序诊断的13例肺诺卡菌病患者的临床特征分析[J]. 临床肺科杂志, 2023, 28(11):1629-1634.
[20] 薛强, 陈俊文, 李平. 慢性阻塞性肺病合并支气管扩张症发生机制[J].临床肺科杂志, 2022, 27(8):1248-1251.
[21] BARNES PJ.COPD 2020: new directions needed[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 319(5): L884-L886.
[22] KURAHARA Y, TACHIBANA K, TSUYUGUCHI K, et al.Pulmonary nocardiosis: a clinical analysis of 59 cases[J]. Respir Investig, 2014, 52(3) : 160-166.
[23] DE LA CRUZ O, MINCES LR, SILVEIRA FP. Experience with linezolid for the treatment of nocardiosis in organ transplant recipients[J]. J Infect, 2015,70(1):44‐51.
[24] JODLOWSKI TZ, MELNYCHUK I, CONRY J.Linezolid for the treatment of Nocardia spp. infections[J]. Ann Pharmacother, 2007;41(10):1694-1699.
[25] 武文明, 崔巧珍, 时东彦, 等. 39株诺卡菌的临床疾病特点及药敏结果分析[J]. 中国抗生素杂志, 2022, 47(12):1326-1330.
[26] MEENA DS, KUMAR D, BOHRA GK, et al.Clinical Characteristics and Treatment Outcome of Central Nervous System Nocardiosis: A Systematic Review of Reported Cases[J]. Med Princ Pract, 2022, 31(4), 333-341.

21例肺诺卡菌病临床特征及耐药性分析

Analysis of strain distribution, clinical characteristics and antimicrobial susceptibility in 21 cases pulmonary nocardiosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李莉, 任美吉, 李宏军, 刘钊, 杨军妍, 齐石, 赵晶. HIV阳性与HIV阴性猴痘患者临床特征分析[J]. 新发传染病电子杂志, 2024, 9(4): 6-11.
[2]	潘世荣, 甘东慧, 张世迁, 黄雅会, 卢亦波, 宋树林. AIDS并发脾脏马尔尼菲篮状菌病及脾结核临床及腹部CT 表现特征分析[J]. 新发传染病电子杂志, 2024, 9(4): 18-22.
[3]	王晓霞, 谭守勇, 黄绍梅, 胡海霞. 80例儿童中枢神经系统结核病临床特征分析[J]. 新发传染病电子杂志, 2024, 9(1): 37-41.
[4]	姚伟明, 王福祥, 卢洪洲. 尼帕病毒的最新研究进展[J]. 新发传染病电子杂志, 2024, 9(1): 60-66.
[5]	汪成, 唐湘熠, 林子洵, 李倩, 卢洪洲. 猴痘合并HIV感染疾病特征的研究进展[J]. 新发传染病电子杂志, 2024, 9(1): 67-72.
[6]	卓文基, 张晨晨, 陈珣珣, 陈燕梅, 余美玲, 魏文静, 徐镠粤, 彭柯皓, 赖晓宇. 2014–2020年广东省老年人结核病的耐药特征分析[J]. 新发传染病电子杂志, 2023, 8(5): 6-10.
[7]	霍雪平, 刘贞君, 谢琴秀. 重症发热伴血小板减少综合征预警指标分析[J]. 新发传染病电子杂志, 2023, 8(5): 41-45.
[8]	陈楚明, 吴伟波, 彭凌, 曹孟丽, 冯世艳, 李建明, 杨柳青, 林元龙, 易云兰, 吴展慧, 王福祥, 卢洪洲. 深圳地区猴痘患者的流行病学及临床特征分析[J]. 新发传染病电子杂志, 2023, 8(4): 1-5.
[9]	黎耀文, 林洁琼, 熊海芮, 范绮梦, 曾洪武. 2020–2021年深圳市儿童医院儿童重症肺炎流行病学与临床特征分析[J]. 新发传染病电子杂志, 2023, 8(3): 53-58.
[10]	袁玲, 汪继平, 李强, 周丽, 肖敏, 方琴. 急性细菌性皮肤和皮肤结构感染患者血液感染危险多因素分析[J]. 新发传染病电子杂志, 2023, 8(2): 63-67.
[11]	张影, 李晓鹤, 陈凤, 袁静. 新型冠状病毒德尔塔和奥密克戎变异株感染患者的临床特征分析[J]. 新发传染病电子杂志, 2022, 7(3): 22-26.
[12]	付亮, 廖伟明, 张惠华, 邓国防. 含异烟肼耐药的耐药结核病临床特点和治疗方案的回顾性队列分析[J]. 新发传染病电子杂志, 2021, 6(4): 306-310.
[13]	陈涛, 王玉香, 郑俊峰, 李天品, 叶飞娣, 叶涛生, 邓国防, 张培泽. Xpert MTB/RIF在呼吸道标本检出极低值并利福平耐药时的诊断可靠性分析[J]. 新发传染病电子杂志, 2021, 6(4): 319-322.
[14]	张淑贞, 李雪宏, 黄海燕, 陈海婷. 基质辅助激光解吸电离飞行时间质谱在幽门螺杆菌检测中的应用[J]. 新发传染病电子杂志, 2021, 6(3): 210-214.
[15]	李莎, 李倩, 韦晓宏, 何耀钦, 卢亦波. 广西南宁地区44例布鲁菌病临床流行病学特征分析[J]. 新发传染病电子杂志, 2021, 6(3): 238-241.